Veeva Vault eTMF Helps Cancer Research UK Improve Clinical Trial Efficiency and Compliance
September 13 2017 - 7:03AM
Business Wire
Leading charity modernizes trial operations to
develop new cancer treatments faster
Veeva Systems (NYSE: VEEV) announced today that Cancer Research
UK selected Veeva Vault eTMF to modernize its clinical trial
processes. The organization currently sponsors and manages
approximately 25 early phase oncology trials through its Centre for
Drug Development. By improving regulatory compliance and increasing
efficiency through active trial master file (TMF) management,
Cancer Research UK aims to optimize development of new treatments
for patients with cancer.
“Our mission is to beat cancer sooner,” said Nigel Blackburn,
director of drug development at Cancer Research UK. “Veeva Vault
eTMF helps us maximize clinical trial efficiency and strengthen our
commercial partnerships so we can accelerate the delivery of the
next generation of treatments to the patients that need them.”
Cancer Research UK’s vision is to accelerate research so that
three in four patients survive cancer by 2034. Regulatory-directed
drug development is key to meeting this objective. As it continued
to evaluate the effectiveness of its clinical operations, Cancer
Research UK identified the opportunity to increase efficiency and
quality in its management of TMF documentation and processes.
The Cancer Research UK Centre for Drug Development was
previously using paper documents in a passive TMF operating model.
Veeva Vault eTMF enables Cancer Research UK to manage all TMF
processes and documents in one system, in real time, as they are
executed. This active TMF operating model maintains the
organization’s TMF in a constant state of inspection readiness.
“Routine inspection preparation used to take as long as 12 days
and archiving documentation took 40 days. Veeva Vault eTMF will
allow us to complete these tasks much faster,” said Stephen
Nabarro, head of clinical operations and data management at Cancer
Research UK. “This allows our team to efficiently manage more
trials, ultimately providing more early phase treatment options for
people with cancer.”
Veeva Vault eTMF is a part of the Veeva Vault Clinical Suite,
the industry's first cloud platform to unify clinical data
management and operations. By combining eTMF with applications for
EDC, eSource, CTMS, study start-up, and site document exchange
built on the Veeva Vault Platform, organizations can eliminate
system silos and streamline end-to-end clinical trial
processes.
The Cancer Research UK Centre for Drug Development is
celebrating 25 years of innovation and partnering with industry and
academia to turn research ideas into novel therapies. The Centre’s
current development portfolio includes 11 small molecule agents and
13 biologicals. It has a track record of involvement in the
development of six marketed drugs to date, including, most
recently, rucaparib (Clovis Oncology) for the treatment of ovarian
cancer.
Additional Information
For more on Veeva Vault eTMF, visit: veeva.com/etmf
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
Follow @Veeva_EU on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About the Cancer Research UK Centre for Drug
Development
Cancer Research UK has an impressive record of developing novel
treatments for cancer. It currently has a portfolio of around 25
new anti-cancer agents in preclinical development, phase I, or
early phase II clinical trials. Since 1982, the Cancer Research UK
Centre for Drug Development, formerly the Drug Development Office,
has taken over 120 potential new anti-cancer agents into clinical
trials in patients, six of which have made it to market and many
others are still in development. These include temozolomide, a drug
discovered by Cancer Research UK scientists that is an effective
treatment for brain cancer. Six other drugs are in late development
phase III trials. This rate of success is comparable to that of any
pharmaceutical company. For further information about Cancer
Research UK's work or to find out how to support the charity,
please call 0300 123 1022 or visit cancerresearchuk.org.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the
global life sciences industry. Committed to innovation, product
excellence, and customer success, Veeva has more than 550
customers, ranging from the world's largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices in Europe, Asia, and Latin
America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the
market demand for and acceptance of Veeva’s products and services,
the results from use of Veeva’s products and services, and general
business conditions, particularly in the life sciences industry.
Any forward-looking statements contained in this press release are
based upon Veeva’s historical performance and its current plans,
estimates, and expectations, and are not a representation that such
plans, estimates, or expectations will be achieved. These
forward-looking statements represent Veeva’s expectations as of the
date of this press announcement. Subsequent events may cause these
expectations to change, and Veeva disclaims any obligation to
update the forward-looking statements in the future. These
forward-looking statements are subject to known and unknown risks
and uncertainties that may cause actual results to differ
materially. Additional risks and uncertainties that could affect
Veeva’s financial results are included under the captions, “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on
Form 10-Q for the period ended April 31, 2017. This is available on
the company’s website at veeva.com under the Investors section and
on the SEC’s website at sec.gov. Further information on potential
risks that could affect actual results will be included in other
filings Veeva makes with the SEC from time to time.
###
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170913005606/en/
Veeva Systems Inc.Sue Glanvillesue@catalystcomms.co.uk+44 (0)
7715 817589orCate Bonthuyscate@catalystcomms.co.uk+44 (0) 7746
546773
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Apr 2023 to Apr 2024